$25 Million Deal! NVIDIA-Backed AI Drugmaker Iambic Therapeutics Announces New Collaboration and Files IPO Prospectus
Today, NVIDIA's market value has reached $4 trillion, becoming the first company in the world to break the $4 trillion market value.
Similarly, the AI pharmaceutical company supported by NVIDIA
Iambic
Therapeu
tics
, reached a new cooperation.
It is reported that Iambic
Therapeu
TICS and NASDAQ-listed biopharmaceutical companies
Revolution Medicines
Reach an agreement,
Leverage its AI-driven platform to develop new drugs.
According to the agreement,
Iambic will use the structures and molecular libraries provided by Revolution Medicines to train a customized version.
Protein-ligand structure prediction model. Additionally,
Revolution will also access other chemical models of the company.
PropANE
。
Iambic Therapeutics will receive $25 million in upfront and milestone payments to support NeuralPLexer model-related services for protein structure prediction.
Iambic Therapeutics was foundedAt the beginning of 2020, the company was founded by two chemistry professors and is headquartered in San Diego, USA.
In June 2024, the company completed a $150 million
Series B financing, the total amount of financing has also accumulated to
$200 million, investors include
NVIDIA, the new global market value leader.
Iambic Therapeutics has built a nameFor InsightA R&D platform combining artificial intelligence and physics for creating more reliable and accurate models to explore the field of chemistry more deeply. The platform is mainly divided into four parts.
NeuralPLexer: For predicting protein-ligand complexes, including conformational responses to binding, revealing new mechanisms of action, allosteric and cryptic pockets
OrbNet: AI-Accelerated Quantum Chemistry for Calculating Protein-Ligand Binding Energy
PropANE: A lead compound parameter optimization model capable of training dozens of drug properties
Magnet: Molecular Design Generation
The company's molecular design software Magnet can perform tasks in one go.1024 molecules, and combined with wet lab experiments to refine predictive molecules through testing results,A design-build-test cycle typically takes 9 days.
NVIDIA is not only
Iambic Therapeutics' investors, both parties began to collaborate on the development of AI + biomedicine models.
Iambic's
Prediction of Protein-Ligand Complex Models
NeuralPLexer
Already deployed to NVIDIA
BioNeMo NIM.
—The End—
Recommended Reading
Summary
Iambic Therapeutics, an NVIDIA-backed AI pharmaceutical company founded in early 2020 and based in San Diego, has entered a new collaboration with Nasdaq-listed Revolution Medicines. Under the agreement, Iambic will leverage Revolution’s structural data and compound libraries to train a customized version of its NeuralPLexer protein–ligand structure prediction model and grant Revolution access to its PropANE chemical optimization model. Iambic will receive 25millioninupfrontandmilestonepayments.Thecompany,whichhasraised200 million to date—including a $150 million Series B in June 2024 with NVIDIA as an investor—has developed the Insight platform integrating AI and physics, featuring NeuralPLexer, OrbNet, PropANE, and Magnet for end-to-end drug discovery. Its NeuralPLexer model is now deployed on NVIDIA’s BioNeMo NIM.